Lead respiratory pharmacist at Leeds Teaching Hospitals NHS Trust.
Role of dual and triple fixed-dose combination inhalers in the treatment of chronic obstructive pulmonary diseaseSubscription
A review of the current evidence, including the safety and efficacy of dual and triple-combination inhalers for the treatment of stable COPD, and their place in therapy.
The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing
Primum non nocereSubscription
We welcome the comments from Stuart Hill providing a counter-argument to the concerns initially raised by the UK Clinical Pharmacy Association Respiratory Group about Relvar Ellipta.
Our concerns with Relvar ElliptaSubscription
Pneumonia: CAP, HAP and other typesSubscription
Tuberculosis: Clinical features and diagnosisSubscription